Grants and Contributions:
The investment will allow the company to add mammalian cell culture (MCC), messenger ribonucleic acid (mRNA) and fill-finish capacity at a single site, including early development capabilities, in a digitally updated facility. It will increase manufacturing footprint and capabilities, improve operational efficiency, and strengthen Canada's ability to develop and manufacture innovative biologic medicines from clinical development through commercial production.
The amendment provides for a 60 month extension. The contribution value was reduced to $93,848,000.
Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services; Facilitate the growth and expansion of firms in Canada; Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.